MarketCap
Boston Scientific Corporation BSX
$ 44.68
0.06%
Facebook
X
Telegram
Boston Scientific Corporation General and Administrative Expenses | BSX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Boston Scientific Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.89 B | 5.98 B | 5.19 B | 4.52 B | 4.36 B | 3.79 B | 3.94 B | 3.57 B | 3.29 B | 3.1 B | 2.87 B | 2.9 B | 2.67 B | 2.54 B | 2.66 B | 2.58 B | 2.64 B | 2.59 B | 2.91 B | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.89 B | 2.54 B | 3.63 B |
Quarterly General and Administrative Expenses Boston Scientific Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.8 B | 1.78 B | 1.74 B | 1.72 B | 1.6 B | 1.56 B | 1.45 B | 1.36 B | 1.24 B | 1.35 B | 1.22 B | - | 1.13 B | 1.16 B | 1.06 B | - | 1.07 B | 1.12 B | 1.02 B | - | 984 M | 798 M | 978 M | - | 1.01 B | 968 M | 869 M | - | 870 M | 886 M | 860 M | - | 800 M | 815 M | 794 M | - | 772 M | 779 M | 716 M | - | 729 M | 700 M | 668 M | - | 741 M | 743 M | 666 M | - | 658 M | 661 M | 631 M | - | 589 M | 648 M | 659 M | - | 629 M | 642 M | 596 M | 634 M | 634 M | 628 M | 665 M | 671 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.8 B | 589 M | 951 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M |  USA |
 |
Bruker Corporation
BRKR
|
946 M | $ 64.0 | 7.26 % | $ 9.72 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
47.1 M | $ 8.7 | 0.06 % | $ 634 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
16.5 M | $ 14.61 | 13.03 % | $ 414 M | USA |
 |
CONMED Corporation
CNMD
|
132 M | $ 45.18 | 3.31 % | $ 1.4 B | USA |
 |
Cytosorbents Corporation
CTSO
|
35.6 M | $ 4.3 | 1.63 % | $ 268 M | USA |
 |
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
43.5 M | $ 16.08 | 0.75 % | $ 576 M | USA |
 |
Medigus Ltd.
MDGS
|
9.96 M | - | 10.28 % | $ 55.5 M | Israel |
 |
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | USA |
 |
Electromed
ELMD
|
42.7 M | $ 27.86 | 1.05 % | $ 230 M | USA |
 |
Establishment Labs Holdings
ESTA
|
165 M | $ 65.58 | 3.69 % | $ 1.94 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 85.73 | 0.32 % | $ 50.1 B | USA |
 |
Nemaura Medical
NMRD
|
5.6 M | - | -17.8 % | $ 2.74 M |  Britain |
 |
AdaptHealth Corp.
AHCO
|
382 M | $ 5.57 | 0.43 % | $ 753 M | USA |
 |
Helius Medical Technologies
HSDT
|
23.1 M | $ 2.9 | 0.69 % | $ 63.9 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
700 M | $ 15.88 | 2.25 % | $ 1.22 B | USA |
 |
Inogen
INGN
|
67.4 M | $ 5.23 | 2.75 % | $ 139 M | USA |
 |
InMode Ltd.
INMD
|
11.7 M | $ 14.19 | 0.21 % | $ 917 M | Israel |
 |
Inspire Medical Systems
INSP
|
625 M | $ 68.81 | 0.59 % | $ 2.02 B | USA |
 |
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
7.73 M | $ 0.63 | 2.51 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
17.8 M | $ 85.2 | 0.08 % | $ 1.08 B | USA |
 |
AxoGen
AXGN
|
44.6 M | $ 43.32 | 0.48 % | $ 1.99 B | USA |
 |
Align Technology
ALGN
|
1.76 B | $ 145.63 | 4.36 % | $ 10.6 B | USA |
|
LENSAR
LNSR
|
45.2 M | $ 7.08 | 0.28 % | $ 84.7 M | USA |
 |
Sientra
SIEN
|
41.5 M | - | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
145 M | - | - | $ 1.07 B | USA |
 |
Medtronic PLC
MDT
|
11.8 B | $ 88.51 | 0.32 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
56.5 M | $ 4.71 | 0.1 % | $ 696 M | USA |
 |
Surgalign Holdings
SRGA
|
95.9 M | - | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
95.3 M | - | - | $ 12.3 B | USA |
 |
Myomo
MYO
|
14 M | $ 1.67 | 1.83 % | $ 69.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
21.6 M | $ 0.66 | 0.45 % | $ 42.8 M | Israel |
 |
InspireMD
NSPR
|
20.7 M | $ 0.7 | 0.37 % | $ 45 M | Israel |
 |
Orthofix Medical
OFIX
|
554 M | $ 9.16 | 0.11 % | $ 363 M |  Curacao |
 |
Outset Medical
OM
|
37.9 M | $ 3.13 | 1.29 % | $ 47.6 K | USA |
 |
Insulet Corporation
PODD
|
1.16 B | $ 135.78 | 0.01 % | $ 9.55 B | USA |
 |
Profound Medical Corp.
PROF
|
32.1 M | $ 5.6 | 1.66 % | $ 169 M | Canada |
 |
Titan Medical
TMDI
|
12.4 M | - | -26.32 % | $ 19.6 M | Canada |
 |
Quanterix Corporation
QTRX
|
138 M | $ 3.18 | 0.63 % | $ 136 M | USA |
 |
Natus Medical Incorporated
NTUS
|
52.8 M | - | 1.94 % | $ 1.05 B | USA |
 |
AVITA Medical
RCEL
|
27.4 M | $ 11.58 | 5.75 % | $ 323 M |  Australia |
 |
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | USA |
 |
Apyx Medical Corporation
APYX
|
15.8 M | $ 2.83 | 1.37 % | $ 116 M | USA |
 |
Sintx Technologies
SINT
|
6.2 M | $ 1.87 | 5.06 % | $ 5.19 M | USA |
 |
Accuray Incorporated
ARAY
|
45.4 M | $ 0.22 | 0.4 % | $ 27 M | USA |
 |
Smith & Nephew plc
SNN
|
3.1 B | $ 26.68 | 0.02 % | $ 23.1 B | Britain |
 |
Inari Medical
NARI
|
361 M | - | - | $ 4.23 B | USA |